The expression levels of BLT2, 5-LOX, and 12-LOX were increased (Fig. 1a) in two human lung cancer cell lines with activating KRAS mutations (A549 with the KrasG12S mutation, and SK-LU-1 with the KrasG12D mutation) compared with a noncancerous control cell line (BEAS-2B, human bronchial epithelial cell line). This evidence concerns the gene LTB4R2 and lung carcinoma.